Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
ZL-1310-001
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- NCT06179069 ↗
- Recruiting
- Zai Lab (Shanghai) Co., Ltd.
- Focused
We haven't built an HCP commentary report on ZL-1310-001 (ZL-1310, atezolizumab and 1 more in SCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ZL-1310-001 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- SCLC
- Interventions
- ZL-1310; Atezolizumab; Carboplatin
- Arms
- Dose Escalation: Part 1A · Experimental
- Dose Expansion: Part 1B · Experimental
- Dose Escalation: Part 1C · Experimental
- Dose Expansion: Arm 1 (Part 2) · Experimental
- Dose Expansion: Arm 2 (Part 2) · Experimental
- Dose Extension: Arm 1 (Part 2) · Experimental
- Doublet Dose Optimization: Arm 1 (Part 3A) · Experimental
- Doublet Dose Optimization: Arm 2 (Part 3A) · Experimental
- Triplet Dose Optimization: Arm 1 (Part 4A) · Experimental
- Triplet Dose Optimization: Arm 2 (Part 4A) · Experimental
- Dose Extension: Part 2-1 · Experimental
- Doublet Dose Extension: Part 3B · Experimental
- Triplet Dose Extension: Part 4B · Experimental
- Enrollment
- 339 (estimated)
- Primary outcomes
- Incidence of Dose Limiting Toxicities of ZL-1310 as a single agent (Part 1A), in combination with Atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)
- Incidence of Treatment Emergent Adverse-Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)
- Incidence of Serious Adverse Events of ZL-1310 as a single agent (Part 1A), in combination with atezolizumab (Part 1B), and in combination with atezolizumab and carboplatin (Part 1C)
- Incidence of Treatment Emergent Adverse Events of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3) and in combination with atezolizumab and carboplatin (Part 4)
- Incidence of Serious Adverse-Events (SAEs) of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)
- Antitumor activity per RECIST v1.1 by investigator's assessment of ZL-1310 as a single agent (Part 2), in combination with atezolizumab (Part 3), and in combination with atezolizumab and carboplatin (Part 4)
- Objective response rate (ORR) per RECIST v1.1 of ZL-1310 as a single agent (Part 2) and in combination with atezolizumab and carboplatin (Part 4)
- Disease control rate (DCR) per RECIST v1.1 of ZL-1310 in combination with atezolizumab
- Sponsor
- Zai Lab (Shanghai) Co., Ltd. with Zai Lab (US) LLC
- Start
- Jan 23, 2024
- Primary completion
- May 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06179069 · updated Oct 16, 2026